Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 2144-2149

  Stupp, R ^a   Tosoni, A ^b   Bromberg, J E C ^c   Hau, P ^d   Campone, M ^e   Gijtenbeek, J ^f   Frenay, M ^g   Breimer, L ^h,k   Wiesinger, H ⁱ   Allgeier, A ^j   van den Bent, M J ^c   Bogdahn, U ^d   van der Graaf, W ^f   Yun, H J ^j,l   Gorlia, T ^j   Lacombe, D ^j   Brandes, A A ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b BELLARIA HOSPITAL   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e Institut Régional du Cancer Nantes Atlantique   (France)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CENTRE ANTOINE LACASSAGNE   (France)

^h BAYER CORPORATION   (United States)

ⁱ BAYER PHARMA AG   (Germany)

^j EORTC DATA CENTER   (Belgium)

^k ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^l Chungnam National University College of Medicine   (South Korea)

more..

Author keywords

Chemotherapy; Glioblastoma; Phase II trial; Recurrent disease; Sagopilone

Indexed keywords

SAGOPILONE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTHERMIA; INFECTION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYOSITIS; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPENIC INFECTION; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BENZOTHIAZOLES; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPOTHILONES; FEMALE; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; YOUNG ADULT;

EID: 80052417101     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq729     Document Type: Article

References (26)

1. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007; 25: 4127-4136.
2. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
3. BarkerII FG II, Chang SM, Gutin PH et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998; 42: 709-720; discussion 720-723.
4. Perry JR, Belanger K, Mason WP et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE Study. J Clin Oncol 2010; 28: 2051-2057.
5. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28: 1168-1174.
6. Brandes AA, Tosoni A, Franceschi E et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 2009; 64: 769-775.
7. Frenay M, Giroux B, Khoury S et al. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 1991; 27: 852-856.
8. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991; 9: 860-864.
9. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572.
10. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
11. Wick W, Weller M, van den Bent M, Stupp R. Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010; 28: e188-e189.
12. Hoffmann J, Vitale I, Buchmann B et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68: 5301-5308.
13. Klar U, Buchmann B, Schwede W et al. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006; 45: 7942-7948.
14. Hoffmann J, Fichtner I, Lemm M et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. J Neurooncol 2009; 11: 158-166.
15. Fogh S, Machtay M, Werner-Wasik M et al. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2010; 77: 1009-1016.
16. Fichtner I, Rolff J, Soong R et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008; 14: 6456-6468.
17. Schmid P, Kiewe P, Possinger K et al. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 2010; 21: 633-639.
18. Arnold D, Voigt W, Kiewe P et al. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 2009; 101: 1241-1247.
19. Silvani A, Gaviani P, Fiumani A et al. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol 2009; 95: 61-64.
20. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
21. Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008; 26: 4659-4665.
22. van den Bent M, Brandes A, Rampling R et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma. Report from EORTC Brain Tumor Group study 26034. J Clin Oncol 2009; 27: 1268-1274.
23. Van Den Bent MJ, Grisold W, Frappaz D et al. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 2003; 14: 1732-1734.
24. Raymond E, Campone M, Stupp R et al. Multicenter phase II pharmacokinetic study of RFS-2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer 2002; 38: 1348-1350.
25. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-745.
26. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.